2026-04-29T04:08:31Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/176332025-05-08T10:37:39Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud author Bethencourt Baute, Juan José author Sanchez-Piedra, Carlos author Ruiz-Montesinos, Dolores author Medrano San Ildefonso, Marta author Rodriguez-Lozano, Carlos author Perez-Pampin, Eva author Ortiz, Ana author Manrique, Sara author Roselló, Rosa author Hernandez, Victoria author Campos, Cristina author Sellas, Agustí author Sifuentes-Giraldo, Walter Alberto author García-González, Javier author Sánchez-Alonso, Fernando author Díaz-González, Federico author Gómez-Reino, Juan Jesús author Bustabad Reyes, Sagrario author BIOBADASER study group 2024-02-08T14:41:53Z 2024-02-08T14:41:53Z 2018-10-10 http://hdl.handle.net/10668/13057 http://hdl.handle.net/20.500.12105/17633 30305158 10.1186/s13075-018-1728-3 1478-6362 Arthritis research & therapy Biologic therapy has changed the prognosis of patients with juvenile idiopathic arthritis (JIA). The aim of this study was to examine the pattern of use, drug survival, and adverse events of biologics in patients with JIA during the period from diagnosis to adulthood. All patients included in BIOBADASER (Spanish Registry for Adverse Events of Biological Therapy in Rheumatic Diseases), a multicenter prospective registry, diagnosed with JIA between 2000 and 2015 were analyzed. Proportions, means, and SDs were used to describe the population. Incidence rates and 95% CIs were calculated to assess adverse events. Kaplan-Meier analysis was used to compare the drug survival rates. A total of 469 patients (46.1% women) were included. Their mean age at diagnosis was 9.4 ± 5.3 years. Their mean age at biologic treatment initiation was 23.9 ± 13.9 years. The pattern of use of biologics during their pediatric years showed a linear increase from 24% in 2000 to 65% in 2014. Biologic withdrawal for disease remission was higher in patients who initiated use biologics prior to 16 years of age than in those who were older (25.7% vs 7.9%, p  Survival and suspension by remission of biologics were higher when these compounds were initiated in patients with JIA who had not yet reached 16 years of age. The incidence rate of serious adverse events in pediatric vs adult patients with JIA treated with biologics was similar; however, a significant increase of infection was observed in patients under 16 years old. eng Biologic treatment Clinical practice Juvenile idiopathic arthritis Safety therapy Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER. research article